Your browser doesn't support javascript.
loading
A narrative review on invasive brain stimulation for treatment-resistant depression
Dandekar, Manoj P.; Diaz, Alexandre P.; Rahman, Ziaur; Silva, Ritele H.; Nahas, Ziad; Aaronson, Scott; Selvaraj, Sudhakar; Fenoy, Albert J.; Sanches, Marsal; Soares, Jair C.; Riva-Posse, Patricio; Quevedo, Joao.
  • Dandekar, Manoj P.; National Institute of Pharmaceutical Education and Research. Department of Pharmacology & Toxicology. Hyderabad. IN
  • Diaz, Alexandre P.; The University of Texas Health Science Center at Houston (UTHealth). Center of Excellence on Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School. Houston. US
  • Rahman, Ziaur; National Institute of Pharmaceutical Education and Research. Department of Pharmacology & Toxicology. Hyderabad. IN
  • Silva, Ritele H.; Universidade do Extremo Sul Catarinense (UNESC). Laboratório de Psiquiatria Translacional, Programa de Pós-Graduação em Ciências da Saúde. Criciúma. BR
  • Nahas, Ziad; University of Minnesota. Department of Psychiatry and Behavioral Sciences. Minneapolis. US
  • Aaronson, Scott; Clinical Research Programs, Sheppard Pratt Health System. Baltimore. US
  • Selvaraj, Sudhakar; The University of Texas Health Science Center at Houston (UTHealth). Center of Excellence on Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School. Houston. US
  • Fenoy, Albert J.; The University of Texas Health Science Center at Houston (UTHealth). Center of Excellence on Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School. Houston. US
  • Sanches, Marsal; The University of Texas Health Science Center at Houston (UTHealth). Center of Excellence on Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School. Houston. US
  • Soares, Jair C.; The University of Texas Health Science Center at Houston (UTHealth). Center of Excellence on Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School. Houston. US
  • Riva-Posse, Patricio; Emory University. Department of Psychiatry and Behavioral Sciences. Atlanta. US
  • Quevedo, Joao; The University of Texas Health Science Center at Houston (UTHealth). Center of Excellence on Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School. Houston. US
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 44(3): 317-330, May-June 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1374608
ABSTRACT
While most patients with depression respond to pharmacotherapy and psychotherapy, about one-third will present treatment resistance to these interventions. For patients with treatment-resistant depression (TRD), invasive neurostimulation therapies such as vagus nerve stimulation, deep brain stimulation, and epidural cortical stimulation may be considered. We performed a narrative review of the published literature to identify papers discussing clinical studies with invasive neurostimulation therapies for TRD. After a database search and title and abstract screening, relevant English-language articles were analyzed. Vagus nerve stimulation, approved by the U.S. Food and Drug Administration as a TRD treatment, may take several months to show therapeutic benefits, and the average response rate varies from 15.2-83%. Deep brain stimulation studies have shown encouraging results, including rapid response rates (> 30%), despite conflicting findings from randomized controlled trials. Several brain regions, such as the subcallosal-cingulate gyrus, nucleus accumbens, ventral capsule/ventral striatum, anterior limb of the internal capsule, medial-forebrain bundle, lateral habenula, inferior-thalamic peduncle, and the bed-nucleus of the stria terminalis have been identified as key targets for TRD management. Epidural cortical stimulation, an invasive intervention with few reported cases, showed positive results (40-60% response), although more extensive trials are needed to confirm its potential in patients with TRD.


Full text: Available Index: LILACS (Americas) Type of study: Controlled clinical trial / Prognostic study Language: English Journal: Braz. J. Psychiatry (São Paulo, 1999, Impr.) Journal subject: Psychiatry Year: 2022 Type: Article / Project document Affiliation country: Brazil / India / United States Institution/Affiliation country: Clinical Research Programs, Sheppard Pratt Health System/US / Emory University/US / National Institute of Pharmaceutical Education and Research/IN / The University of Texas Health Science Center at Houston (UTHealth)/US / Universidade do Extremo Sul Catarinense (UNESC)/BR / University of Minnesota/US

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Type of study: Controlled clinical trial / Prognostic study Language: English Journal: Braz. J. Psychiatry (São Paulo, 1999, Impr.) Journal subject: Psychiatry Year: 2022 Type: Article / Project document Affiliation country: Brazil / India / United States Institution/Affiliation country: Clinical Research Programs, Sheppard Pratt Health System/US / Emory University/US / National Institute of Pharmaceutical Education and Research/IN / The University of Texas Health Science Center at Houston (UTHealth)/US / Universidade do Extremo Sul Catarinense (UNESC)/BR / University of Minnesota/US